Navigation Links
Cancer deaths continue to drop
Date:7/7/2010

ATLANTA July 7, 2010 The continued drop in overall cancer mortality rates over the last 20 years has averted more than three-quarters of a million (767,000) cancer deaths according to a new report from the American Cancer Society. The American Cancer Society's annual Cancer Statistics article reports that the overall death rate from cancer in the United States in 2007 was 178.4 per 100,000, a relative decrease of 1.3 percent from 2006, when the rate was 180.7 per 100,000, continuing a trend that began in 1991 for men and 1992 for women. In that time, mortality rates have decreased by 21 percent among men and by 12 percent among women, due primarily to declines in smoking, better treatments, and earlier detection of cancer.

The figures come from Cancer Statistics 2010, published early online in CA: A Cancer Journal for Clinicians. The report and its consumer version, Cancer Facts & Figures 2010, include the estimated numbers of new cancer cases and deaths for 2010. Society epidemiologists predict there will be 1,529,560 new cancer cases (789,620 in men and 739,940 in women) and 569,490 cancer deaths (299,200 in men and 270,290 in women) in the United States in 2010.

Other highlights of Cancer Statistics 2010 include:

  • Cancers of the lung, prostate, and colorectum in men and cancers of the lung, breast, and colorectum in women continue to be the most common fatal cancers. These four cancers account for half of the total cancer deaths among men and women.

  • Among men, cancers of the prostate, lung, and colon will account for just over half (52 percent) of all newly diagnosed cancers. Prostate cancer alone will account for one in four (28 percent, 217,730 cases) of all cancer diagnoses in men. About nine in ten of these new cases of prostate cancer are expected to be diagnosed at local or regional stages, for which five-year relative survival approaches 100 percent.

  • The three most commonly diagnosed type
    '/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Ryan Hamner's Free Hear The Heart Tour Sweeping The South Four-Time Cancer Survivor, Sings Hope To Others
2. Length of biological marker associated with risk of cancer
3. Breast, Colon Cancer Screening Rates High, But Not High Enough
4. Shorter Telomere Length Again Linked to Cancer
5. Scientists find link between estrogen metabolism pathway and breast cancer risk
6. Revolutionary therapy slows tumor growth in advanced breast cancer, Penn research reports
7. People Living With Lung Cancer Are Too Often Stigmatised Because Of Link To Smoking
8. Stanford Who's Who & Anthony Casimano Make Donation to Help Support National Organization, CancerCare
9. Why are blacks more likely to die from cancer diagnosis?
10. DNA mutation rates raise curtain on cause of cancer
11. Cancer stem cells are not 1 size fits all, lung cancer models show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Those who self-injure, commonly ... misdiagnosed and therefore aren’t receiving effective treatment ... Jacksonville-based addiction treatment center Lakeview Health has ... Lakeview Professional Lecture Series to counselors, physicians, ... complicated condition. , “Self-injurious behaviors ...
(Date:2/27/2015)... Orlando, FL (PRWEB) February 27, 2015 Today, ... the KAJ Brothers , along with LXR Organics ... with the END IT Campaign to raise awareness and promote ... According to statistics provided by the END IT Coalition, slavery ... dollars per year and exists in 167 countries around the ...
(Date:2/27/2015)... On March 2-4, the Mesothelioma Applied ... Institute (NCI) will co-host the annual International Symposium ... Health (NIH), in Bethesda, Maryland. The event comprises ... professionals and scientists who specialize in mesothelioma, while ... including patients, their families, and caregivers. , The ...
(Date:2/27/2015)... Clinovo, a leading provider of cloud-based eClinical ... (EDC) at the CALBIO2015 conference taking place ... 3rd at Booth # 141. , ClinCapture ... edit-check builder allowing Clinical Trials Managers to create CRFs ... any programming experience. Clinovo’s new pricing model offers a ...
(Date:2/27/2015)... February 27, 2015 Altec Products, Inc., ... has been chosen as their doc-link for Dynamics Partner ... and other complimentary solutions for their customers in all ... credit unions. Altec and BPW have worked side-by-side to ... to Dynamics GP. , “We are so impressed by ...
Breaking Medicine News(10 mins):Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... REGISTER NOW , , CHICAGO, July 9 ... of Chicago, the American Cancer Society Charity Runner Team is ... , , , "The Society is thrilled to ... Marathon," said Alison Tibbits, project manager, fundraising resources, American Cancer ...
... July 9 /PRNewswire-USNewswire/ -- Skyrocketing prescription drug prices are ... to cut back on the basics, like food and utilities, in ... survey, as brand name drugs see record price increases, the majority ... to pay for their medications in the coming year. ...
... Corporation (OTC Bulletin Board: CONX), a worldwide developer and ... AspirinWorks(R) Test at the XXII Congress and the 55th ... International Society on Thrombosis and Haemostasis (ISTH). The ISTH ... Boston Convention & Exhibition Center. , , Corgenix ...
... Specialty care physicians can improve the health of ... providing e-consultations and treatment plan recommendations with primary care ... in the British Medical Journal. , ... demonstrated that specialists can take a more active role ...
... of SEIU UHW will hold a news conference at 3 p.m. ... to release newly obtained information showing that ousted union President Sal ... attorney that some of the actions may be illegal but took ... to cover them up. , , The documents detailing ...
... July 9 Today, Bayer HealthCare Pharmaceuticals launched the ... make infusion of recombinant factor VIII easier for both ... The centerpiece of the program is an adjustable cuff ... to practice the technique of self-injection without actually infusing ...
Cached Medicine News:Health News:Calling All Runners: Join the Fight Against Cancer 2Health News:High Rx Costs Hammering Illinois' 50+ Population 2Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2009 ISTH Meeting 2Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2009 ISTH Meeting 3Health News:Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 2Health News:Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 3Health News:Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 4Health News:Newly Obtained Information Shows That Ousted Union Leaders Plotted and Covered Up Wrongdoing 2Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 2Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 3Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 4Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 5
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... highlighted findings from a pre-clinical study published in ... Sciences ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ... anti-PD-L1 antibody (a checkpoint inhibitor), suppression of tumor ... be achieved when treating certain hematologic cancers and ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... LEXINGTON, Mass. , Feb. 27, 2015   ... GEVA ), a biopharmaceutical company developing therapeutic products ... Rare Disorders™ (NORD™), the European Organisation for Rare ... around the world in observing Rare Disease Day. ... each year, patient organizations, industry, and other participants ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... three large PEGINTRON(TM) clinical studies address key questions ... 27 Schering-Plough Corporation (NYSE: SGP ... large PEGINTRON(TM) (peginterferon alfa-2b) clinical studies address longstanding ... provide important insights. The results of the ...
... - With half as many injections, in two ... the primary efficacy endpoint of sustained virologic response ... receiving 900-mcg Albuferon had comparable rates of serious ... 3 trials, versus peginterferon alfa-2a -- Submission of ...
Cached Medicine Technology:Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 9Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 10Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 11Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 2Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 3Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 4Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 5Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 6Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 7Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 8
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: